Gba Gene Glucocerebrosidase is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| Full Name | Glucocerebrosidase |
|---|
| Chromosomal Location | 1q21.3 |
|---|
| NCBI Gene ID | 2629 |
|---|
| OMIM | 230800 |
|---|
| Ensembl ID | ENSG00000177628 |
|---|
| UniProt | P04062 |
|---|
| Associated Diseases | Parkinson's Disease, Gaucher Disease, Dementia with Lewy Bodies |
|---|
GBA (Glucocerebrosidase), located on chromosome 1q21.3, encodes the lysosomal enzyme glucocerebrosidase (glucosylceramidase), which catalyzes the hydrolysis of glucosylceramide to glucose and ceramide[^1]. GBA mutations cause Gaucher disease, the most common lysosomal storage disorder, and are also the most significant genetic risk factor for Parkinson's disease identified to date[^2]. Heterozygous GBA mutations increase PD risk by 5-20 fold, making it a critical gene for understanding the link between lysosomal dysfunction and neurodegeneration[^3].
The GBA gene encodes glucocerebrosidase (GCase), a 536-amino acid lysosomal hydrolase:
- Enzymatic activity: Hydrolyzes glucosylceramide (GlcCer) to glucose and ceramide in the lysosome.
- Lipid metabolism: Critical for degradation of glucosylceramide and glucosylsphingosine.
- Protein quality control: Involved in autophagy and lysosomal function.
- Mitochondrial function: GBA mutations affect mitochondrial health and energy metabolism.
- Alpha-synuclein clearance: GCase interacts with alpha-synuclein; impaired function leads to its accumulation.
GCase is synthesized in the endoplasmic reticulum, traffics through the Golgi, and is delivered to lysosomes where it requires the activator protein saposin C for optimal activity. The enzyme exists as a homodimer and requires proper glycosylation for stability and function.
| Feature |
Details |
| Molecular weight |
~60 kDa (precursor), ~56 kDa (mature) |
| Structure |
Beta-glucosidase fold with TIM barrel |
| Active site |
E235, E309 (catalytic residues) |
| N-glycosylation |
4 potential sites |
| Lysosomal targeting |
Mannose-6-phosphate modification |
- Risk factor: Heterozygous GBA mutations are the strongest genetic risk factor for PD.
- Prevalence: 5-10% of PD patients carry GBA mutations; up to 15-20% in certain populations.
- Mechanism: Reduced glucocerebrosidase activity leads to:
- Accumulation of glucosylceramide and glucosylsphingosine
- Impaired autophagy-lysosomal pathway
- Enhanced alpha-synuclein aggregation
- Mitochondrial dysfunction
- Endoplasmic reticulum stress
| Mutation |
Effect |
Frequency |
Notes |
| N370S |
Reduced activity |
Most common |
Mild Gaucher, high PD risk |
| L444P |
Severe loss |
Common |
Severe Gaucher, high PD risk |
| 84GG |
Null allele |
Common |
Severe Gaucher |
| IVS2+1 |
Splicing defect |
Common |
Severe Gaucher |
| R463C |
Reduced activity |
Rare |
Moderate PD risk |
| E326K |
Reduced activity |
Common |
Modest PD risk |
| T369M |
Reduced activity |
Rare |
Modest PD risk |
- Inheritance: Autosomal recessive
- Types: Type 1 (non-neuronopathic), Type 2 (acute neuronopathic), Type 3 (chronic neuronopathic)
- Symptoms: Hepatosplenomegaly, cytopenia, bone disease, neurological symptoms (types 2/3)
- Treatment: Enzyme replacement therapy (ERT), substrate reduction therapy (SRT), chaperone therapy
- Prevalence: GBA mutations found in 10-20% of DLB cases.
- Phenotype: Earlier onset, more severe cognitive impairment, more rapid progression.
- Pathology: Often co-pathology with alpha-synuclein and tau.
- Parkinsonism Plus Syndromes: Higher frequency in progressive supranuclear palsy, corticobasal degeneration.
- Multiple System Atrophy: Some association with GBA variants.
- Alzheimer's Disease: Modest association with some GBA variants.
- High expression: Liver, spleen, kidney, brain (neurons, microglia).
- Cellular localization: Lysosomal membrane and luminal.
- Regional specificity: Moderate expression in cortex, basal ganglia, substantia nigra.
- Cell types: Neurons, astrocytes, microglia, oligodendrocytes.
- Regulation: Transcription factor EB (TFEB) regulates GBA expression via lysosomal biogenesis.
- Ambroxol (mecapton): Pharmacological chaperone that increases GCase activity; in clinical trials for PD.
- Venglustat (GZ161): Substrate reduction therapy; being evaluated for PD.
- Gene therapy: AAV-GBA being developed for both Gaucher and PD.
- Eliglustat: Reduces glucosylceramide production.
- Venglustat: Inhibits glucosylceramide synthase.
- ERT + alpha-synuclein targeting: Rationale for combining GCase enhancement with anti-aggregation strategies.
- ** chaperone + small molecule**: Enhance GCase activity while reducing substrate burden.
- Gba knockout: embryonic lethal; conditional knockouts show neurodegeneration.
- Gba heterozygote: Reduced activity, increased alpha-synuclein aggregation.
- Gba N370S knock-in: Mild reduction in activity, age-related neurodegeneration.
- Gba + alpha-synuclein double transgenic: Synergistic effects on aggregation and neurodegeneration.
- C. elegans: GBA knockdown leads to alpha-synuclein aggregation.
- Drosophila: GBA models show neurodegeneration and locomotor deficits.
- Sidransky E, et al. (2009). "Multicenter analysis of glucocerebra" (2009). "Multicenter analysis of glucocerebrosidase mutations in Parkinson disease." N Engl J Med. PMID:19843450
- Schapdahe S, et al. (2014). "Glucocerebrosidase mutations and synucleinopathies." Nat Rev Neurol. PMID:24839849
- Bennett M, et al. (2020). "GBA variants and Parkinson disease: mechanisms and therapeutics." J Mol Neurosci. PMID:32157632
- Mazzulli JR, et al. (2011). " Gaucher disease glucocerebrosidase and alpha-synuclein form a bidirectional pathogenic loop in synucleinopathies." Cell. PMID:21700325
- Aflaki E, et al. (2016). "A new therapeutic approach to Parkinson disease." Ann Neurol. PMID:26891044
- Sardi SP, et al. (2013). "Augmenting CNS glucocerebrosidase." Nat Med. PMID:23535936
The study of Gba Gene Glucocerebrosidase has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
-
- 1 Brady RO, et al. (1965). "Enzyme replacement in Gaucher disease." Proc Natl Acad Sci USA. PMID:14262789.
- 2 Sidransky E, et al. (2009). Multicenter analysis of glucocerebrosidase mutations in Parkinson disease. N Engl J Med. PMID:19843450.
- 3 Schapdahe S, et al. (2014). Glucocerebrosidase mutations and synucleinopathies. Nat Rev Neurol. PMID:24839849.
- 4 Mazzulli JR, et al. (2011). Gaucher disease glucocerebrosidase and alpha-synuclein form a bidirectional pathogenic loop. Cell. PMID:21700325.
- 5 Bennett M, et al. (2020). GBA variants and Parkinson disease. J Mol Neurosci. PMID:32157632.
- 6 Sardi SP, et al. (2013). Augmenting CNS glucocerebrosidase. Nat Med. PMID:23535936.
-